SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Carlson Kristina) "

Sökning: WFRF:(Carlson Kristina)

  • Resultat 11-20 av 98
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
11.
  •  
12.
  • Burt, Richard K., et al. (författare)
  • Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis : A Randomized Clinical Trial
  • 2019
  • Ingår i: Journal of the American Medical Association (JAMA). - : AMER MEDICAL ASSOC. - 0098-7484 .- 1538-3598. ; 321:2, s. 165-174
  • Tidskriftsartikel (refereegranskat)abstract
    • IMPORTANCE Hematopoietic stem cell transplantation (HSCT) represents a potentially useful approach to slow or prevent progressive disability in relapsing-remitting multiple sclerosis (MS).OBJECTIVE To compare the effect of nonmyeloablative HSCT vs disease-modifying therapy (DMT) on disease progression.DESIGN, SETTING, AND PARTICIPANTS Between September 20, 2005, and July 7, 2016, a total of 110 patients with relapsing-remitting MS, at least 2 relapses while receiving DMT in the prior year, and an Expanded Disability Status Scale (EDSS; score range, 0-10 [10 = worst neurologic disability]) score of 2.0 to 6.0 were randomized at 4 US, European, and South American centers. Final follow-up occurred in January 2018 and database lock in February 2018.INTERVENTIONS Patients were randomized to receive HSCT along with cyclophosphamide (200mg/kg) and antithymocyte globulin (6mg/kg) (n = 55) or DMT of higher efficacy or a different class than DMT taken during the previous year (n = 55).MAIN OUTCOMES AND MEASURES The primary end point was disease progression, defined as an EDSS score increase after at least 1 year of 1.0 point or more (minimal clinically important difference, 0.5) on 2 evaluations 6 months apart, with differences in time to progression estimated as hazard ratios. RESULTS Among 110 randomized patients (73 [66%] women; mean age, 36 [SD, 8.6] years), 103 remained in the trial, with 98 evaluated at 1 year and 23 evaluated yearly for 5 years (median follow-up, 2 years; mean, 2.8 years). Disease progression occurred in 3 patients in the HSCT group and 34 patients in the DMT group. Median time to progression could not be calculated in the HSCT group because of too few events; it was 24 months (interquartile range, 18-48 months) in the DMT group (hazard ratio, 0.07; 95% CI, 0.02-0.24; P < .001). During the first year, mean EDSS scores decreased (improved) from 3.38 to 2.36 in the HSCT group and increased (worsened) from 3.31 to 3.98 in the DMT group (between-group mean difference,-1.7; 95% CI,-2.03 to -1.29; P < .001). There were no deaths and no patients who received HSCT developed nonhematopoietic grade 4 toxicities (such as myocardial infarction, sepsis, or other disabling or potential life-threatening events).CONCLUSIONS AND RELEVANCE In this preliminary study of patients with relapsing-remitting MS, nonmyeloablative HSCT, compared with DMT, resulted in prolonged time to disease progression. Further research is needed to replicate these findings and to assess long-term outcomes and safety.
  •  
13.
  • Carlson, Johan, 1972, et al. (författare)
  • Minimizing Dimensional Variation and Robot Traveling Time in Welding Stations
  • 2014
  • Ingår i: Procedia CIRP. - : Elsevier BV. - 2212-8271. ; 23:C, s. 77-82
  • Konferensbidrag (refereegranskat)abstract
    • Complex assembled products as an automotive car body consist of about 300 sheet metal parts joined by up to 4000 spot welds. In the body factory, there are several hundred robots organized into lines of welding stations. The distribution of welds between robots and the welding sequences have a significant influence on both dimensional quality and throughput. Therefore, this paper proposes a novel method for quality and throughput optimization based on a systematic search algorithm which exploits properties of the welding process. It uses approximated lower bounds to speed up the search and to estimate the quality of the solution. The method is successfully tested on reference assemblies, including detailed fixtures, welding robots and guns.
  •  
14.
  •  
15.
  • Cesaro, Simone, et al. (författare)
  • Second allogeneic stem cell transplant for aplastic anaemia : a retrospective study by the severe aplastic anaemia working party of the European society for blood and marrow transplantation
  • 2015
  • Ingår i: British Journal of Haematology. - : Wiley. - 0007-1048 .- 1365-2141. ; 171:4, s. 606-614
  • Tidskriftsartikel (refereegranskat)abstract
    • We analysed the outcome of a second allogeneic haematopoietic stem cell transplant (alloHSCT) in 162 patients reported to the European Society for Blood and Marrow Transplantation between 1998 and 2009. Donor origin was a sibling in 110 and an unrelated donor in 52 transplants, respectively. The stem cell source was bone marrow in 31% and peripheral blood in 69% of transplants. The same donor as for the first alloHSCT was used in 81% of transplants whereas a change in the choice of stem cell source was reported in 56% of patients, mainly from bone marrow to peripheral blood. Neutrophil and platelet engraftment occurred in 85% and 72% of patients, after a median time of 15 and 17days, respectively. Grade II-IV acute graft-versus-host disease (GVHD) and chronic GVHD occurred in 21% and 37% of patients, respectively. Graft failure (GF) occurred in 42 patients (26%). After a median follow-up of 3.5years, the 5-year overall survival (OS) was 60.7%. In multivariate analysis, the only factor significantly associated with a better outcome was a Karnofsky/Lansky score 80 (higher OS). We conclude that a second alloHSCT is feasible rescue option for GF in SAA, with a successful outcome in 60% of cases.
  •  
16.
  • Daikeler, Thomas, et al. (författare)
  • New autoimmune diseases after cord blood transplantation : a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation
  • 2013
  • Ingår i: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 121:6, s. 1059-1064
  • Tidskriftsartikel (refereegranskat)abstract
    • To describe the incidence, risk factors, and treatment of autoimmune diseases (ADs) occurring after cord blood transplantation (CBT), we analyzed both CBT recipients reported to EUROCORD who had developed at least 1 new AD and those who had not. Fifty-two of 726 reported patients developed at least 1 AD within 212 days (range, 27-4267) after CBT. Cumulative incidence of ADs after CBT was 5.0% +/- 1% at 1 year and 6.6% +/- 1% at 5 years. Patients developing ADs were younger and had more nonmalignant diseases (P < .001). ADs target hematopoietic (autoimmune hemolytic anemia, n = 20; Evans syndrome, n = 9; autoimmune thrombocytopenia, n = 11; and immune neutropenia, n = 1) and other tissues (thyroiditis, n = 3; psoriasis, n = 2; Graves disease, n = 1; membranous glomerulonephritis, n = 2; rheumatoid arthritis, n = 1; ulcerative colitis, n = 1; and systemic lupus erythematosus, n = 1). Four patients developed 2 ADs (3 cases of immune thrombocytopenia followed by autoimmune hemolytic anemia and 1 Evans syndrome with rheumatoid arthritis). By multivariate analysis, the main risk factor for developing an AD was nonmalignant disease as an indication for CBT (P = .0001). Hematologic ADs were most often treated with steroids, rituximab, and cyclosporine. With a median follow-up of 26 months (range, 2-91), 6 of 52 patients died as a consequence of ADs. We conclude that CBT may be followed by potentially life-threatening, mainly hematologic ADs.
  •  
17.
  • De Greef, Julien, et al. (författare)
  • Risk factors for Nocardia infection among allogeneic hematopoietic cell transplant recipients : A case-control study of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation
  • 2024
  • Ingår i: Journal of Infection. - : Elsevier. - 0163-4453 .- 1532-2742. ; 88:6
  • Tidskriftsartikel (refereegranskat)abstract
    • ObjectivesNocardiosis is a rare but life-threatening infection after hematopoietic cell transplantation (HCT). We aimed at identifying risk factors for nocardiosis after allogeneic HCT and clarifying the effect of trimethoprim-sulfamethoxazole prophylaxis on its occurrence.MethodsWe performed a retrospective multicenter case-control study of patients diagnosed with nocardiosis after allogeneic HCT between January 2000 and December 2018. For each case, two controls were matched by center, transplant date, and age group. Multivariable analysis was conducted using conditional logistic regression to identify potential risk factors for nocardiosis. Kaplan-Meier survival curves of cases and controls were compared using log-rank tests.ResultsSixty-four cases and 128 controls were included. Nocardiosis occurred at a median of 9 months after allogeneic HCT (interquartile range: 5–18). After adjustment for potential confounders in a multivariable model, Nocardia infection was associated with tacrolimus use (adjusted odds ratio [aOR] 9.9, 95 % confidence interval [95 % CI]: 1.6–62.7), lymphocyte count < 500/µL (aOR 8.9, 95 % CI: 2.3–34.7), male sex (aOR 8.1, 95 % CI: 2.1–31.5), recent use of systemic corticosteroids (aOR 7.9, 95 % CI: 2.2–28.2), and recent CMV infection (aOR 4.3, 95 % CI: 1.2–15.9). Conversely, use of trimethoprim-sulfamethoxazole prophylaxis was associated with a significantly decreased risk of nocardiosis (aOR 0.2, 95 % CI: 0.1–0.8). HCT recipients who developed nocardiosis had a significantly decreased survival, as compared with controls (12-month survival: 58 % and 90 %, respectively; p < 0.0001).ConclusionsWe identified six factors independently associated with the occurrence of nocardiosis among allogeneic HCT recipients. In particular, trimethoprim-sulfamethoxazole prophylaxis was found to protect against nocardiosis.
  •  
18.
  • Diaz, Ben P., et al. (författare)
  • Seasonal mixed layer depth shapes phytoplankton physiology, viral production, and accumulation in the North Atlantic
  • 2021
  • Ingår i: Nature Communications. - : Nature Publishing Group. - 2041-1723. ; 12:1
  • Tidskriftsartikel (refereegranskat)abstract
    • Seasonal shifts in phytoplankton accumulation and loss largely follow changes in mixed layer depth, but the impact of mixed layer depth on cell physiology remains unexplored. Here, we investigate the physiological state of phytoplankton populations associated with distinct bloom phases and mixing regimes in the North Atlantic. Stratification and deep mixing alter community physiology and viral production, effectively shaping accumulation rates. Communities in relatively deep, early-spring mixed layers are characterized by low levels of stress and high accumulation rates, while those in the recently shallowed mixed layers in late-spring have high levels of oxidative stress. Prolonged stratification into early autumn manifests in negative accumulation rates, along with pronounced signatures of compromised membranes, death-related protease activity, virus production, nutrient drawdown, and lipid markers indicative of nutrient stress. Positive accumulation renews during mixed layer deepening with transition into winter, concomitant with enhanced nutrient supply and lessened viral pressure. Phytoplankton are important primary producers. Here the authors investigate phytoplankton physiological changes associated with bloom phases and mixing regimes in the North Atlantic, finding that stratification and deep mixing shape accumulation rates by altering physiology and viral production.
  •  
19.
  •  
20.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 11-20 av 98
Typ av publikation
tidskriftsartikel (77)
konferensbidrag (12)
annan publikation (4)
rapport (3)
bok (1)
doktorsavhandling (1)
visa fler...
visa färre...
Typ av innehåll
refereegranskat (83)
övrigt vetenskapligt/konstnärligt (15)
Författare/redaktör
Carlson, Kristina (63)
Carlson, Johan, 1972 (16)
Wärmefjord, Kristina ... (16)
Lenhoff, Stig (12)
Nahi, Hareth (11)
Turesson, Ingemar (10)
visa fler...
Mellqvist, Ulf-Henri ... (9)
Juliusson, Gunnar (7)
Hansson, Markus (7)
Burman, Joachim, 197 ... (7)
Linder, Olle (7)
Waage, Anders (6)
Rosengren, Sara (6)
Ljungman, Per (6)
Ahlberg, Lucia (6)
Österborg, Anders (5)
Sörensen, Jens (5)
Abildgaard, Niels (5)
Nilsson, Kenneth (5)
Jernberg-Wiklund, He ... (5)
Strömberg, Thomas (5)
Westin, Jan (5)
Hägglund, Hans (4)
Kero, Tanja (4)
Vedin, Ola (4)
Fagius, Jan (4)
Beguin, Yves (3)
Antoni, Gunnar (3)
Platonov, Pyotr G (3)
Andersson, Per-Ola, ... (3)
Åkerfeldt, Torbjörn (3)
Lundqvist, Kristina (3)
Ljungman, P (3)
Wikström, Gerhard (3)
Brune, Mats, 1950 (3)
Näsman, Per (3)
Einarsdottir, Sigrun (3)
Gilljam, Thomas (3)
Lubberink, Mark (3)
Axelsson, Per (3)
Edvardsen, Thor (3)
Edelvik, Fredrik, 19 ... (3)
Svendsen, Jesper H. (3)
Blaise, Didier (3)
Jensen, Henrik K. (3)
Carlson, Jan (3)
Hammarberg, Anna (3)
Labopin, Myriam (3)
Haugaa, Kristina H. (3)
Bundgaard, Henning (3)
visa färre...
Lärosäte
Uppsala universitet (67)
Karolinska Institutet (31)
Linköpings universitet (23)
Lunds universitet (22)
Chalmers tekniska högskola (17)
Göteborgs universitet (14)
visa fler...
Umeå universitet (10)
Örebro universitet (5)
Kungliga Tekniska Högskolan (3)
Mälardalens universitet (3)
Linnéuniversitetet (3)
Stockholms universitet (2)
Högskolan i Halmstad (1)
Malmö universitet (1)
Södertörns högskola (1)
visa färre...
Språk
Engelska (92)
Odefinierat språk (4)
Svenska (2)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (56)
Teknik (16)
Naturvetenskap (15)
Samhällsvetenskap (2)
Humaniora (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy